Syndax Pharmaceuticals, Inc.
NASDAQ:SNDXBiotechnology
+$0.13 today
- Market cap
- $770.64M
- Beta
- 0.39
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$2.81
Volume 3.46M
Average 1.70M
SNDX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Syndax Pharmaceuticals, Inc.NASDAQ: SNDX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$30.82M, compared with -$83.76M a year earlier. Trailing-twelve-month EBITDA was -$162.5M.
Context
- EBITDA amounted to 146.0% of revenue in FY2025, down 1179.3 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of -$177.87M (+29.3%) for the fiscal year ending Dec 2026, a step up from the +19.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$30.82M-101.3% QoQ
- Last fiscal yearDec 2025
- -$251.63M+19.8% YoY
- LTMMar 2026
- -$162.5M+50.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +63.2% | +57.0% | -6.2 pp |
| 1 year | +19.8% | +29.3% | +9.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (251.63M) USD
- Year-over-year change
- +19.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (251.63M) | +19.8% |
| FY2024 | 2024-12-31 | (313.82M) | -50.1% |
| FY2023 | 2023-12-31 | (209.14M) | -43.1% |
| FY2022 | 2022-12-31 | (146.17M) | -644.0% |
| FY2021 | 2021-12-31 | 26.87M | — |
EBITDA vs competitors
How SNDX compares with its peers on the latest reported figures
- SNDX's LTM Mar 2026 EBITDA of -$162.5M is the 9th highest of the 11 companies compared; the peer median is -$105.15M.
- Its year-over-year change of +50.0% is the 3rd highest of 11, against a peer median of -4.4%.
- EBITDA amounts to 74.8% of revenue for SNDX, versus a peer median of 74.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $322.61M | +243.1% | — | 46.0% | |
| LTM Sep 2026 | $57.08M | +205.8% | — | 21.5% | |
| LTM Mar 2026 | -$50.64M | -7.0% | — | 32.2% | |
| LTM Mar 2026 | -$57.67M | -232.5% | — | 162.2% | |
| LTM Mar 2026 | -$86.7M | +32.0% | — | — | |
| LTM Jun 2026 | -$123.6M | -14.3% | — | 117.7% | |
| LTM Jun 2026 | -$127.04M | +36.8% | — | 74.8% | |
| LTM Mar 2026 | -$134.03M | -1.8% | — | — | |
| LTM Mar 2026 | -$162.5M | +50.0% | — | 74.8% | |
| LTM Dec 2025 | -$311.38M | -33.2% | — | — | |
| LTM Jun 2026 | -$419M | -48.6% | — | 358.1% | |
| Peer median (excluding SNDX) | -$105.15M | -4.4% | — | 74.8% | |
Competitors are the stored peer set for SNDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 139.71M | 0 | 0 | 23.68M | 172.35M |
| Cost of Revenue | 0 | 0 | 0 | 826K | 6.97M |
| Gross Profit | 139.71M | 0 | 0 | 22.85M | 165.38M |
| Gross Margin | 100.0% | — | — | 96.5% | 96.0% |
| Research & Development | 88.25M | 118.5M | 163.03M | 241.65M | 258.78M |
| Selling, General & Admin | 25.24M | 33.26M | 66.92M | 120.88M | 179.68M |
| Operating Expenses | 113.49M | 151.76M | 229.95M | 362.53M | 438.47M |
| Depreciation & Amortization | 43K | 33K | 12K | 8K | 6K |
| EBITDA | 26.87M | (146.17M) | (209.14M) | (313.82M) | (251.63M) |
| EBITDA Margin | 19.2% | — | — | -1325.3% | -146.0% |
| Operating Income | 26.22M | (151.76M) | (229.95M) | (339.67M) | (273.08M) |
| Operating Margin | 18.8% | — | — | -1434.4% | -158.4% |
| Interest Income | 403K | 5.87M | 21.16M | 26.09M | 22.73M |
| Interest Expense | 1.9M | 3.14M | 208K | 4.93M | 33.79M |
| Other Income / Expenses | (1.29M) | 2.42M | 20.59M | 20.91M | (12.34M) |
| Income Before Tax | 24.93M | (149.34M) | (209.36M) | (318.76M) | (285.42M) |
| Pre-Tax Margin | 17.8% | — | — | -1346.1% | -165.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | 24.93M | (149.34M) | (209.36M) | (318.76M) | (285.42M) |
| Net Margin | 17.8% | — | — | -1346.1% | -165.6% |
| EPS (Basic) | 0.48 | (2.46) | (2.98) | (3.73) | (3.29) |
| EPS (Diluted) | 0.48 | (2.46) | (2.98) | (3.73) | (3.29) |
| Weighted Avg Shares | 52.06M | 60.76M | 70.37M | 85.62M | 86.63M |
| Weighted Avg Shares (Diluted) | 52.06M | 60.76M | 70.37M | 85.62M | 86.63M |
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
Intrinsic Alpha fair value
Locked
Current Price
$8.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.